Literature DB >> 8072768

Possible role of nitric oxide in malarial immunosuppression.

K A Rockett1, M M Awburn, E J Rockett, W B Cowden, I A Clark.   

Abstract

We have tested the hypothesis that nitric oxide may be responsible for the immunosuppression reported during malaria infections. We first showed that reactive nitrogen intermediates, which indicate nitric oxide generation, were increased in the plasma of Plasmodium vinckei-infected mice. We next found that Concanavalin A-induced proliferation of spleen cells from these mice was reduced compared with that observed in uninfected animals. The addition of NG-methyl-L-arginine (L-NMMA) for the duration of the cultures restored the malarial proliferative response to normal. We then tested the effect of oral L-NMMA on the proliferative response of P. chabaudi-infected mice to a human red blood cell lysate. The secondary response to this antigen, measured as spleen cell proliferation in vitro ten days after immunization and when there was no discernible parasitaemia, remained normal in L-NMMA-treated P. chabaudi mice, but was decreased in the untreated infected mice. These results suggest a role for nitric oxide in malarial immunosuppression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8072768     DOI: 10.1111/j.1365-3024.1994.tb00346.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  39 in total

1.  Stage-dependent role of nitric oxide in control of Trypanosoma cruzi infection.

Authors:  M Saeftel; B Fleischer; A Hoerauf
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

2.  Deficiency in tumor necrosis factor alpha activity does not impair early protective Th1 responses against blood-stage malaria.

Authors:  H Sam; Z Su; M M Stevenson
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  Transforming growth factor beta-induced failure of resistance to infection with blood-stage Plasmodium chabaudi in mice.

Authors:  N Tsutsui; T Kamiyama
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

4.  Altered immune response of interferon regulatory factor 1-deficient mice against Plasmodium berghei blood-stage malaria infection.

Authors:  R S Tan; C Feng; Y Asano; A U Kara
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

5.  The impact of l-arginine supplementation on the enteral phase of experimental Trichinella spiralis infection in treated and untreated mice.

Authors:  Hanaa O Fadl; Noha M Amin; Hanaa Wanas; Shimaa Saad El-Din; Heba A Ibrahim; Basma Emad Aboulhoda; Nardeen Zakka Bocktor
Journal:  J Parasit Dis       Date:  2020-07-25

6.  Interleukin-4 is essential for the control of microfilariae in murine infection with the filaria Litomosoides sigmodontis.

Authors:  L Volkmann; M Saeftel; O Bain; K Fischer; B Fleischer; A Hoerauf
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

7.  Role of gamma interferon in cellular immune response against murine Encephalitozoon cuniculi infection.

Authors:  I A Khan; M Moretto
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

8.  Lactobacillus bulgaricus prevents intestinal epithelial cell injury caused by Enterobacter sakazakii-induced nitric oxide both in vitro and in the newborn rat model of necrotizing enterocolitis.

Authors:  Catherine J Hunter; Monica Williams; Mikael Petrosyan; Yigit Guner; Rahul Mittal; Dennis Mock; Jeffrey S Upperman; Henri R Ford; Nemani V Prasadarao
Journal:  Infect Immun       Date:  2008-12-15       Impact factor: 3.441

Review 9.  Pathogenesis of malaria and clinically similar conditions.

Authors:  Ian A Clark; Lisa M Alleva; Alison C Mills; William B Cowden
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

10.  Effect of nitric oxide releasing drugs on the intensity of infection during experimental trichinellosis in mice.

Authors:  Elzbieta Wandurska-Nowak; Edward Hadaś; Monika Derda; Waldemar Wojt
Journal:  Parasitol Res       Date:  2003-03-12       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.